ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Osman O. Al-Radi
Vivek Rao
Terrence Yau
Richard D. Weisel
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Al-Radi, O. O.
Right arrow Articles by Weisel, R. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Al-Radi, O. O.
Right arrow Articles by Weisel, R. D.
Related Collections
Right arrow Pericardium

Ann Thorac Surg 2003;75:S674-S677
© 2003 The Society of Thoracic Surgeons

I: Pathophysiology of ischemic-reperfusion injury

Cardiac cell transplantation: closer to bedside

Osman O. Al-Radi, MBBSa, Vivek Rao, MD, PhDa*, Ren-ke Li, PhDa, Terrence Yau, MD, MSa, Richard D. Weisel, MDa

a Division of Cardiac Surgery, Toronto General Hospital, University Health Network, Toronto, Ontario, Canada

* Address reprint requests to Vivek Rao, MD, PhD, 200 Elizabeth St, 14-222, Toronto, ON, Canada.
e-mail: vivek.rao{at}uhn.on.ca

Presented at the 3rd International Symposium on Myocardial Protection From Surgical Ischemic-Reperfusion Injury, Asheville, NC, June 2–6, 2002.

Abstract

The current treatment for heart failure is inadequate for a large number of patients who do not qualify for heart transplantation or innovative surgical therapy. Cellular augmentation of damaged myocardium has been actively investigated in the past decade. Cells best suited for the task are skeletal myoblasts and bone morrow mesenchymal stem cells. Both cell types are autologous, abundant, and easy to harvest. The focus of early human trials will be to establish the safety of an effective cellular dose. Trials conducted with an inadequate cellular dose may discredit cell therapy because of lack of effect but, more importantly, may provide a false sense of safety because of a lack of adverse events secondary to a small inoculating dose.




This article has been cited by other articles:


Home page
 Card Surg AdultHome page
R. P. Gallegos and R. M. Bolman III
Stem Cell Induced Regeneration of Myocardium
Card. Surg. Adult, January 1, 2008; 3(2008): 1657 - 1668.
[Full Text]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
V. Rao
Stem cell transplantation for ischemic cardiomyopathy: Hope or hype?
J. Thorac. Cardiovasc. Surg., December 1, 2005; 130(6): 1492 - 1493.
[Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
A. N. Patel, L. Geffner, R. F. Vina, J. Saslavsky, H. C. Urschel Jr, R. Kormos, and F. Benetti
Surgical treatment for congestive heart failure with autologous adult stem cell transplantation: A prospective randomized study
J. Thorac. Cardiovasc. Surg., December 1, 2005; 130(6): 1631 - 1638.
[Abstract] [Full Text] [PDF]

Home page
 Eur J Heart FailHome page
L. Ye, H. Kh. Haider, S. Jiang, L. H. Ling, R. Ge, P. K. Law, and E. K.W. Sim
Reversal of myocardial injury using genetically modulated human skeletal myoblasts in a rodent cryoinjured heart model
Eur J Heart Fail, October 1, 2005; 7(6): 945 - 952.
[Abstract] [Full Text] [PDF]

Home page
 Eur J Heart FailHome page
H. Piao, T.-J. Youn, J.-S. Kwon, Y.-H. Kim, J.-W. Bae, Bora-Sohn, D.-W. Kim, M.-C. Cho, M.-M. Lee, and Y.-B. Park
Effects of bone marrow derived mesenchymal stem cells transplantation in acutely infarcting myocardium
Eur J Heart Fail, August 1, 2005; 7(5): 730 - 738.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
S. Fazel, G. H.L. Tang, D. Angoulvant, M. Cimini, R. D. Weisel, R.-K. Li, and T. M. Yau
Current Status of Cellular Therapy for Ischemic Heart Disease
Ann. Thorac. Surg., June 1, 2005; 79(6): S2238 - S2247.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
L. Barandon, T. Couffinhal, P. Dufourcq, P. Alzieu, D. Daret, C. Deville, and C. Duplaa
Repair of Myocardial Infarction by Epicardial Deposition of Bone Marrow Cell-Coated Muscle Patch in a Murine Model
Ann. Thorac. Surg., October 1, 2004; 78(4): 1409 - 1417.
[Abstract] [Full Text] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
L. Barandon
Editorial comment: Cellular cardiomyoplasty: 'inject is easy, demonstrate is complicated'
Eur. J. Cardiothorac. Surg., March 1, 2004; 25(3): 350 - 351.
[Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
Y.-F. Xiao, J.-Y. Min, and J. P. Morgan
Immunosuppression and xenotransplantation of cells for cardiac repair
Ann. Thorac. Surg., February 1, 2004; 77(2): 737 - 744.
[Abstract] [Full Text] [PDF]

Home page
 J. Physiol.Home page
J. F. Heubach, E. M. Graf, J. Leutheuser, M. Bock, B. Balana, I. Zahanich, T. Christ, S. Boxberger, E. Wettwer, and U. Ravens
Electrophysiological properties of human mesenchymal stem cells
J. Physiol., February 1, 2004; 554(3): 659 - 672.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2003 by The Society of Thoracic Surgeons.